Zhifei Longcom Recombinant COVID-19 Vaccine Receives Conditional Marketing Approval in Belarus

 On January 3, local time, Zhifei longcom Recombinant COVID-19 Vaccine (CHO Cell) was approved for Conditional Marketing Approval by the Ministry of Health (MoH) of Belarus.

                                                                                                                                                                  (Source: The official website of the MoH of Belarus)

Previously, Zhifei Longcom Recombinant COVID-19 Vaccine (CHO Cell) has received Emergency Use Authorization in Indonesia and Colombia, booster dose authorization in Indonesia, and Marketing Approval in Uzbekistan and Kenya. More than 300 million doses have been used at home and abroad, making a positive contribution to the fight against COVID-19.

In the future, Zhifei will continue to promote the internationalization strategy, actively carry out product international registration and clinical trial layout, strive to make vaccines by Zhifei with greater numbers, safter profile and better quality benefit people worldwide, and contribute more Chinese strength to global public health and epidemic prevention and control.